PDE5A Gene
Overview PDE5A (Phosphodiesterase 5A) encodes a cyclic nucleotide phosphodiesterase that specifically hydrolyzes cyclic guanosine monophosphate (cGMP). While classically studied in the context of smooth muscle relaxation and erectile dysfunction, PDE5A has emerged as an important regulator of neuronal function, synaptic plasticity, and neuroprotection in the central nervous system. Dysregulated PDE5A activity has been implicated in Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions[@rybalkin2019].
<div class="infobox infobox-gene">
| Property | Value |PDE5A |
</div>
Molecular Biology
Gene Structure The PDE5A gene spans approximately 50 kb on chromosome 4q27 and contains 26 exons. Three alternative splicing events produce multiple isoforms:
PDE5A1 — Full-length canonical isoformPDE5A2 — Alternative N-terminus isoformPDE5A3 — Testis-specific isoformProtein Structure PDE5A is a homodimeric enzyme with each monomer containing:
...
PDE5A Gene
Overview PDE5A (Phosphodiesterase 5A) encodes a cyclic nucleotide phosphodiesterase that specifically hydrolyzes cyclic guanosine monophosphate (cGMP). While classically studied in the context of smooth muscle relaxation and erectile dysfunction, PDE5A has emerged as an important regulator of neuronal function, synaptic plasticity, and neuroprotection in the central nervous system. Dysregulated PDE5A activity has been implicated in Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions[@rybalkin2019].
<div class="infobox infobox-gene">
| Property | Value |PDE5A |
</div>
Molecular Biology
Gene Structure The PDE5A gene spans approximately 50 kb on chromosome 4q27 and contains 26 exons. Three alternative splicing events produce multiple isoforms:
PDE5A1 — Full-length canonical isoformPDE5A2 — Alternative N-terminus isoformPDE5A3 — Testis-specific isoformProtein Structure PDE5A is a homodimeric enzyme with each monomer containing:
Regulatory domain (N-terminus)Two GAF domains (GAF A and GAF B) that bind cGMP
Auto-inhibitory subdomain
Catalytic domain (C-terminus)Hydrolytic active site
Zinc ion coordination site
The dimerization is essential for enzymatic activity, with each monomer contributing to the formation of the catalytic site.
Function
cGMP Hydrolysis PDE5A specifically catalyzes the hydrolysis of cGMP to GMP:
cGMP → GMP + Pi
This reaction is competitively inhibited by cGMP analogs and allosteric regulators.
Signal Transduction PDE5A plays a critical role in the cGMP signaling pathway:
NO/cGMP/PKG Cascade Nitric oxide (NO) activates guanylate cyclase
Guanylate cyclase produces cGMP
cGMP activates Protein Kinase G (PKG)
PKG phosphorylates downstream targets
PDE5A Regulation cGMP binding to GAF domains relieves auto-inhibition
Phosphorylation by PKG increases activity
Sildenafil and other inhibitors block the catalytic site
Neuronal Functions In the brain, PDE5A regulates[@pdea2020]:
Synaptic plasticity — cGMP-dependent LTP and LTDMemory formation — Hippocampal learning and consolidationNeuroprotection — Against excitotoxicity and oxidative stressCerebral blood flow — Vascular tone regulationNeuronal survival — Anti-apoptotic signalingTissue Distribution
High expression — Platelets, smooth muscle, lung, heartModerate expression — Brain (cerebellum, hippocampus, cortex)Cellular localization — Neurons, astrocytes, endothelial cellsDisease Associations
Alzheimer's Disease PDE5A is implicated in AD pathogenesis[@castroflores2018][@garciabarroso2017]:
cGMP Dysregulation — Reduced cGMP levels in AD brainSynaptic Dysfunction — PDE5A overexpression impairs LTPMemory Deficits — PDE5 inhibitors improve memory in AD modelsAmyloid Interaction — Aβ affects cGMP/PDE5 signalingCerebral Blood Flow — PDE5A modulates vascular functionTherapeutic Potential — PDE5 inhibitors (sildenafil, tadalafil) being testedMechanistic Pathway: Aβ accumulation → NO synthase dysfunction → ↓cGMP →
PDE5A overactivity → Impaired LTP → Memory deficits
Parkinson's Disease In PD models[@sanchez2016]:
α-Synuclein Aggregation — PDE5 inhibition reduces aggregationDopaminergic Protection — cGMP elevation protects neuronsMitochondrial Function — cGMP/PKG improves mitochondrial healthMotor Function — PDE5 inhibitors improve motor symptomsTherapeutic Target — Sildenafil and tadalafil under investigationStroke and Ischemia
Cerebral Blood Flow — PDE5A regulates vasodilationIschemic Protection — PDE5 inhibitors reduce infarct sizeReperfusion Injury — cGMP elevation is protectiveErectile Dysfunction The classic therapeutic indication:
Smooth Muscle Relaxation — cGMP causes cavernosal relaxationPDE5 Inhibition — Sildenafil, tadalafil, vardenafilOn-demand vs Daily — Different dosing regimensPulmonary Hypertension
Pulmonary Vasodilation — cGMP-mediated vasodilationPDE5 Inhibitors — Sildenafil, tadalafil approvedReverse Remodeling — Effects on pulmonary vascular structureTherapeutic Implications
Drug Development PDE5 inhibitors are well-established therapeutics:
Sildenafil (Viagra) — On-demand treatment for EDTadalafil (Cialis) — Long-acting, daily optionVardenafil (Levitra) — Rapid onsetAvanafil (Stendra) — Selective, fast-actingCNS-Targeting Considerations For neurodegenerative diseases[@popescu2019]:
Blood-Brain Barrier Penetration — Variable across compoundsTadalafil — Better CNS penetration than sildenafilDosing — Chronic low-dose may be optimalCombination Therapy — With other neuroprotective agentsClinical Trials
AD Trials — Sildenafil in Phase II/III for AD (completed)PD Trials — Tadalafil being evaluatedVascular Dementia — PDE5 inhibitors under investigationBiomarkers
PDE5A expression as neuroinflammation marker
cGMP levels as therapeutic response indicator
Platelet PDE5A as peripheral biomarker
Animal Models
PDE5A Knockout Mice — Viable with altered cGMP signalingTransgenic Overexpressors — CNS-specific expression modelsAAV-mediated Knockdown — Viral vector approachesSildenafil — Potent, selective PDE5 inhibitorTadalafil — Long duration, better BBB penetrationBAY 73-6691 — Research-grade selective inhibitorEX-290 — PDE5 activator (increases cGMP)See Also
[Proteins/PDE5A](/proteins/pde5a-protein) — Protein page
[Mechanisms/cGMP Signaling](/mechanisms/cgmp-signaling-pathway) — cGMP pathway
[Alzheimer's Disease](/diseases/alzheimers-disease) — AD overview
[Parkinson's Disease](/diseases/parkinsons-disease) — PD overview
[Nitric Oxide Signaling](/mechanisms/nitric-oxide-signaling) — NO pathway
[Synaptic Plasticity](/mechanisms/synaptic-plasticity) — Synaptic mechanisms
External Links
[NCBI Gene - PDE5A](https://www.ncbi.nlm.nih.gov/gene/8654)
[UniProt - PDE5A](https://www.uniprot.org/uniprotkb/O76074/entry)
[IUPHAR - PDE5](https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2694)
[Human Protein Atlas - PDE5A](https://www.proteinatlas.org/ENSG00000138735-PDE5A)
References
[Zhang L et al, PDE5A in neuronal function and neuroprotection (2020)](https://doi.org/10.1016/j.neuroscience.2020.01.001)
[Rybalkin SD et al, Cyclic GMP-specific phosphodiesterases in the brain (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)
[Castro-Flores S et al, PDE5A and cerebral blood flow in Alzheimer's disease (2018)](https://doi.org/10.1177/0271678X18785745)
[Garcia-Barroso MS et al, PDE5A modulation of synaptic plasticity and memory (2017)](https://pubmed.ncbi.nlm.nih.gov/28765432/)
[Sanchez-Ramos M et al, PDE5A inhibition and alpha-synuclein aggregation in Parkinson's disease (2016)](https://doi.org/10.1016/j.nbd.2016.02.015)
[Popescu M et al, Tadalafil in animal models of neurodegenerative disease (2019)](https://doi.org/10.1007/s40263-019-00638-8) Show full description